BTLA and B-cell chronic lymphocytic leukemia: Instead, an anti-BTLA monoclonal antibody has been shown to deplete chronic lymphocytic leukemia (CLL) and boost natural killer (NK) cell-mediated responses ex vivo by increasing IFN-γ production and cytotoxic capability in antibody-dependent cytotoxicity (ADCC).